Lv1
20 积分 2023-08-20 加入
HER2 and urothelial carcinoma: current understanding and future directions
1天前
已完结
Towards biomarker-driven therapies for urothelial carcinoma
1天前
已完结
T cell-engaging therapies — BiTEs and beyond
9天前
已完结
HER2-targeted therapies beyond breast cancer — an update
13天前
已完结
Glofitamab for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
22天前
已完结
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
22天前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
24天前
已完结
Zanzalintinib plus atezolizumab versus regorafenib in refractory colorectal cancer (STELLAR-303): a randomised, open-label, phase 3 trial
25天前
已完结
Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study
1个月前
已完结
Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study
1个月前
已完结
皖公网安备34019202002308
